Back to news

GSK rises after strong Q2 results and growth plan update

Investivoq PriceTracker

GSK plc (GSK) is up 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver was a strong second-quarter earnings release that showed better-than-expected operating momentum, helped by growth in specialty medicines and vaccines. Investor sentiment also appeared to improve after management paired the results with a longer-term growth plan and reaffirmed its full-year outlook.

Details:

  • GSK announced second-quarter 2026 results on July 28, with total sales of about £8.4 billion, including solid growth in specialty medicines and vaccines.
  • The company said it was maintaining its 2026 guidance, including expected turnover growth of 3% to 5% and core operating profit growth of 7% to 9% at constant exchange rates.
  • Management also used the update to outline plans to accelerate research and development and deepen the late-stage pipeline, including a target of more than 20 phase III trial starts in 2026.
  • The combination of an earnings beat, stable guidance, and a clearer long-term growth roadmap likely gave investors a reason to bid the shares higher.

    • Sources:

    GSK, SEC, Investing.com

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    EARLY ACCESS
    Receive GSK Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $GSK Hedge Fund Activity

    We have seen 456 institutional investors add shares of $GSK stock to their portfolio, and 416 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • DODGE & COX removed 10,465,460 shares (-17.8%) from their portfolio in Q2 2026, for an estimated $548,599,413
    • HOLOCENE ADVISORS, LP removed 5,518,433 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $289,276,257
    • ACADIAN ASSET MANAGEMENT LLC removed 5,136,651 shares (-43.5%) from their portfolio in Q2 2026, for an estimated $269,263,245
    • MORGAN STANLEY removed 3,373,089 shares (-30.6%) from their portfolio in Q2 2026, for an estimated $176,817,325
    • GOLDMAN SACHS GROUP INC removed 3,217,672 shares (-33.6%) from their portfolio in Q2 2026, for an estimated $168,670,366
    • FMR LLC removed 2,700,005 shares (-4.0%) from their portfolio in Q2 2026, for an estimated $141,534,262
    • POINT72 ASSET MANAGEMENT, L.P. added 2,652,881 shares (+inf%) to their portfolio in Q2 2026, for an estimated $139,064,022

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.